LIFT: Longitudinal Investigation of Cancer-related Fatigue

Sponsor
German Cancer Research Center (Other)
Overall Status
Withdrawn
CT.gov ID
NCT03211273
Collaborator
University Hospital Heidelberg (Other)
0
75

Study Details

Study Description

Brief Summary

In the LIFT study 2000 cancer patients will be recruited at 6 months after diagnosis and extensively surveyed over five years on factors that are associated with fatigue.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The LIFT study aims to comprehensively investigate characteristics, determinants, and long-term course of fatigue. In addition, information shall be gained on the current state of fatigue treatment and care in Germany and on the needs of affected patients.

    Data will be collected by mailed or online questionnaires at 6, 9, and 12 months as well as 2, 3, 4 and 5 years post-diagnosis from 2000 cancer patients. Besides questionnaires on socio-demographic, clinical and patient reported outcomes, saliva samples will be collected in order to gain new insights into biological mechanisms. Moreover, detailed data on screening, diagnosis and counseling as well as therapies offered and administered to reduce fatigue will be surveyed, as well as the patients' state of knowledge, perception and prevailing needs regarding fatigue. Tumor and cancer therapy data will be extracted from the Epidemiological Cancer Registry.

    The results of the LIFT study aim to contribute to an improved, evidence-based and individualized treatment to avoid and ease cancer-related fatigue and will further promote patient-oriented offers and treatments.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    0 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    A Prospective, Observational Study to Investigate Longterm Courses, Patterns, Determinants and State of Treatment of Cancer-related Fatigue in Germany (LIFT)
    Anticipated Study Start Date :
    Mar 1, 2019
    Anticipated Primary Completion Date :
    Jun 1, 2021
    Anticipated Study Completion Date :
    Jun 1, 2025

    Arms and Interventions

    Arm Intervention/Treatment
    Patient cohort

    Newly diagnosed breast, ovarian or colon cancer patients recruited 6 months post-diagnosis and followed up to 5 years post-diagnosis. No intervention.

    Outcome Measures

    Primary Outcome Measures

    1. Fatigue severity [from diagnosis to 1 year post-diagnosis]

      assessed by EORTC QLQ-FA12 (European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire)

    2. Impact of fatigue [from diagnosis to 1 year post-diagnosis]

      assessed by the Brief Fatigue Inventory (BFI)

    3. State of fatigue management [from diagnosis to 1 year post-diagnosis]

      Questionnaire assessing the adherence to the National Comprehensive Cancer Network (NCCN) guidelines regarding management of cancer-related fatigue

    Secondary Outcome Measures

    1. Quality of life functions and symptoms [6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis]

      assessed by EORTC QLQ-C30

    2. Sleep problems [6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis]

      assessed by Pittsburgh Sleep Quality Index (PSQI)

    3. Depression [6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis]

      assessed by Patient Health Questionnaire (PHQ-9)

    4. Body mass index [6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis]

      calculated from weight and height

    5. Total physical activity [6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis]

      assessed by a questionnaire regarding walking, cycling, and exercise behavior

    6. Diurnal cortisol rhythm [1 year post-diagnosis]

      assessed in saliva

    7. Return to work [6, 12 months and 2, 3, 4, and 5 years post-diagnosis]

      assessed by a questions regarding occupational issues

    8. Hot flashes [6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis]

      assessed only for women

    9. Anxiety [6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis]

      assessed by the Generalized Anxiety Disorder Questionnaire (GAD-7)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • ≥ 18 years of age

    • Diagnosed with a primary tumor of breast, ovarian, or colon cancer

    • Time since first diagnosis is 4 - 6 months

    • Having received or currently receiving at least one of the following treatments: surgery, chemotherapy, radiotherapy, hormone therapy, or immune therapy.

    • Able to understand and follow the study protocol.

    Exclusion Criteria:

    • Any additional malignant or unclear neoplasm or carcinoma in situ at or since time of diagnosis of the considered primary tumor

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • German Cancer Research Center
    • University Hospital Heidelberg

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    German Cancer Research Center
    ClinicalTrials.gov Identifier:
    NCT03211273
    Other Study ID Numbers:
    • LIFT
    First Posted:
    Jul 7, 2017
    Last Update Posted:
    Aug 28, 2019
    Last Verified:
    Aug 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 28, 2019